Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $135.93 million. The enterprise value is $2.10 million.
Important Dates
The next estimated earnings date is Thursday, March 26, 2026, after market close.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | Jan 16, 2026 |
Share Statistics
ORMP has 39.80 million shares outstanding. The number of shares has increased by 3.29% in one year.
| Current Share Class | 39.80M |
| Shares Outstanding | 39.80M |
| Shares Change (YoY) | +3.29% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 18.79% |
| Owned by Institutions (%) | 20.30% |
| Float | 29.16M |
Valuation Ratios
The trailing PE ratio is 3.33.
| PE Ratio | 3.33 |
| Forward PE | n/a |
| PS Ratio | 67.96 |
| Forward PS | n/a |
| PB Ratio | 0.69 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 0.05 |
| EV / Sales | 1.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.24, with a Debt / Equity ratio of 0.00.
| Current Ratio | 22.24 |
| Quick Ratio | 22.08 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 24.48% and return on invested capital (ROIC) is -16.35%.
| Return on Equity (ROE) | 24.48% |
| Return on Assets (ROA) | -4.22% |
| Return on Invested Capital (ROIC) | -16.35% |
| Return on Capital Employed (ROCE) | -6.07% |
| Weighted Average Cost of Capital (WACC) | 11.37% |
| Revenue Per Employee | $500,000 |
| Profits Per Employee | $10.96M |
| Employee Count | 4 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ORMP has paid $11.94 million in taxes.
| Income Tax | 11.94M |
| Effective Tax Rate | 21.41% |
Stock Price Statistics
The stock price has increased by +61.85% in the last 52 weeks. The beta is 1.31, so ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | +61.85% |
| 50-Day Moving Average | 3.28 |
| 200-Day Moving Average | 2.55 |
| Relative Strength Index (RSI) | 52.52 |
| Average Volume (20 Days) | 170,889 |
Short Selling Information
The latest short interest is 540,151, so 1.36% of the outstanding shares have been sold short.
| Short Interest | 540,151 |
| Short Previous Month | 644,912 |
| Short % of Shares Out | 1.36% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 1.90 |
Income Statement
In the last 12 months, ORMP had revenue of $2.00 million and earned $43.85 million in profits. Earnings per share was $1.03.
| Revenue | 2.00M |
| Gross Profit | 13,000 |
| Operating Income | -13.01M |
| Pretax Income | 55.74M |
| Net Income | 43.85M |
| EBITDA | -12.89M |
| EBIT | -13.01M |
| Earnings Per Share (EPS) | $1.03 |
Full Income StatementBalance Sheet
The company has $134.69 million in cash and $860,000 in debt, with a net cash position of $133.83 million or $3.36 per share.
| Cash & Cash Equivalents | 134.69M |
| Total Debt | 860,000 |
| Net Cash | 133.83M |
| Net Cash Per Share | $3.36 |
| Equity (Book Value) | 202.33M |
| Book Value Per Share | 4.98 |
| Working Capital | 130.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.59 million and capital expenditures -$18,000, giving a free cash flow of -$10.61 million.
| Operating Cash Flow | -10.59M |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -10.61M |
| FCF Per Share | -$0.27 |
Full Cash Flow StatementMargins
Gross margin is 0.65%, with operating and profit margins of -650.55% and 2,192.60%.
| Gross Margin | 0.65% |
| Operating Margin | -650.55% |
| Pretax Margin | 2,787.20% |
| Profit Margin | 2,192.60% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $0.25, which amounts to a dividend yield of 7.32%.
| Dividend Per Share | $0.25 |
| Dividend Yield | 7.32% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 24.34% |
| Buyback Yield | -3.29% |
| Shareholder Yield | 4.03% |
| Earnings Yield | 32.26% |
| FCF Yield | -7.80% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on January 23, 2013. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jan 23, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
ORMP has an Altman Z-Score of 2.8 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.8 |
| Piotroski F-Score | 1 |
